GE HealthCare (GEHC) Begins Phase 2/3 Trial for Innovative MRI Contrast Agent

GE HealthCare Technologies Inc. (NASDAQ:GEHC) is one of the best NASDAQ stocks with the highest upside potential. On April 23, GE HealthCare reached a clinical milestone with the first patient dosed in the Phase 2/3 LUMINA trial for mangaciclanol, an innovative manganese-based MRI contrast agent. The trial, currently underway at the Mayo Clinic, evaluates the agent under an FDA Fast Track designation, which is intended to accelerate the development of products addressing significant unmet medical needs.

Mangaciclanol is designed for both adult and pediatric patients to help clinicians visualize lesions with abnormal vascularity in the central nervous system and other parts of the body. If approved, mangaciclanol has the potential to transform the medical imaging market by serving as a viable alternative to (or even a replacement for) gadolinium-based contrast agents/GBCAs, which are the current global standard.

Unlike gadolinium, a rare-earth metal that has raised medical concerns regarding long-term retention in the body, manganese is a naturally occurring element that is autoregulated by the human system. Early clinical data indicates that mangaciclanol offers diagnostic capabilities similar to market-leading agents while using a macrocyclic cage-like structure to minimize the risk of elemental retention.

GE HealthCare (GEHC) Begins Phase 2/3 Trial for Innovative MRI Contrast Agent

Africa Studio/Shutterstock.com

GE HealthCare Technologies Inc. (NASDAQ:GEHC) is a healthcare company with a focus on various products, services, and digital solutions made for diagnoses and treatments. The company operates through Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics segments.

While we acknowledge the risk and potential of GEHC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GEHC and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.